Umeclidinium (Incruse Ellipta)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Umeclidinium (Incruse Ellipta), covering 2016-02-15 to 2016-02-15. Get the full timeline:
Most recent: Clinical Trial Update: A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]